“Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis” (2023) SKIN The Journal of Cutaneous Medicine, 7(2), p. s154. doi:10.25251/skin.7.supp.154.